AI Engines For more Details: Perplexity Kagi Labs You
Rank | Probiotic | Impact |
---|---|---|
species | Streptococcus thermophilus | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
Streptococcus | genus | Decreases | 👪 Source Study | |
Streptococcus thermophilus | species | Decreases | 📓 Source Study | |
Streptococcus thermophilus ASCC 1275 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus CNRZ1066 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus JIM 8232 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus LMD-9 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus LMG 18311 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus M17PTZA496 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus MN-ZLW-002 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus MTH17CL396 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus ND03 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus TH1436 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus TH982 | strain | Decreases | 👶 Source Study | |
Streptococcus thermophilus TH985 | strain | Decreases | 👶 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Ankylosing spondylitis | 0.3 | 0.3 | |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Atrial fibrillation | 0.3 | 0.3 | |
Autism | 0.3 | 0.3 | 0 |
Barrett esophagus cancer | 0.3 | -0.3 | |
Carcinoma | 0.3 | 0.3 | |
Celiac Disease | 0.3 | 0.3 | |
Cerebral Palsy | 0.3 | 0.3 | |
Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | |
Chronic Urticaria (Hives) | 0.3 | 0.3 | |
Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
COVID-19 | 0.8 | 0.3 | 1.67 |
deep vein thrombosis | 0.3 | -0.3 | |
Depression | 0.3 | 0.3 | 0 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 0.3 | -0.3 | |
Endometriosis | 0.3 | 0.3 | |
Epilepsy | 0.3 | 0.3 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
Glioblastoma | 0.3 | -0.3 | |
Halitosis | 0.3 | -0.3 | |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
hypertension (High Blood Pressure | 0.3 | 0.3 | 0 |
Inflammatory Bowel Disease | 0.3 | 0.3 | |
Insomnia | 0.3 | 0.3 | |
Liver Cirrhosis | 0.3 | 0.3 | 0 |
Long COVID | 0.3 | 0.3 | |
ME/CFS with IBS | 0.3 | 0.3 | |
ME/CFS without IBS | 0.3 | 0.3 | |
Metabolic Syndrome | 0.3 | 0.3 | 0 |
Mood Disorders | 0.3 | 0.3 | 0 |
multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
Multiple Sclerosis | 0.8 | 0.3 | 1.67 |
Neuropathy (all types) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.3 | |
Obesity | 0.3 | 0.3 | |
obsessive-compulsive disorder | 0.3 | 0.3 | |
Osteoarthritis | 0.3 | 0.3 | |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 0.3 | 0.3 | 0 |
Psoriasis | 0.3 | 0.3 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | 0.3 | |
Sjögren syndrome | 0.3 | 0.3 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Systemic Lupus Erythematosus | 0.3 | 0.3 | |
Type 1 Diabetes | 0.3 | -0.3 | |
Type 2 Diabetes | 0.3 | 0.3 | 0 |
Ulcerative colitis | 0.3 | 0.3 | |
Unhealthy Ageing | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.